Compare FWRD & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWRD | NBTX |
|---|---|---|
| Founded | 1981 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 871.2M | 1.0B |
| IPO Year | 1993 | 2020 |
| Metric | FWRD | NBTX |
|---|---|---|
| Price | $26.85 | $24.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $35.00 | $26.00 |
| AVG Volume (30 Days) | ★ 587.6K | 22.3K |
| Earning Date | 02-26-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,496,734,000.00 | $11,930,711.00 |
| Revenue This Year | $2.78 | N/A |
| Revenue Next Year | $4.76 | $145.24 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.54 | N/A |
| 52 Week Low | $9.79 | $2.95 |
| 52 Week High | $32.47 | $30.35 |
| Indicator | FWRD | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.99 | 60.40 |
| Support Level | $25.94 | $22.76 |
| Resistance Level | $31.18 | $25.55 |
| Average True Range (ATR) | 1.51 | 1.13 |
| MACD | -0.22 | 0.40 |
| Stochastic Oscillator | 31.58 | 72.91 |
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in the United States, Canada, and Mexico.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.